Abstract Details

Title Histoplasmosis of the central nervous system in an immunocompetent male

Topic Infectious Disease

Presentation(s) P12 - Poster Session 12 (12:00 PM-1:00 PM)

Poster/Presentation
Number 13-011

Objective We present a case of Histoplasmosa capsulatum CNS infection in an immunocompetent male. The patient is a 39 year old immunocompetent man with a history of spinal TB, hydrocephalus, and ventriculoperitoneal shunt placement (August 2019) who was admitted with fever and abdominal pain in the absence of meningismus or altered mental status. CT scan of the abdomen revealed a fluid collection in the abdomen that was suspected to be secondary to CSF collection versus abscess formation. The VP shunt was removed and an EVD was placed. His hospital course was complicated by partial small bowel obstruction. CSF fluid studies and cultures were obtained on admission and the VP shunt catheter tip was also cultured post removal. The CSF glucose was 53, protein 222, WBC 30 with 95% lymphocytes. CSF and catheter tip cultures were positive for yeast species and patient was treated empirically with liposomal amphotericin B. He was transitioned to voriconizole and when the speciation revealed histoplasmosa capsulatum he was returned to liposomal amphotericin B. In our literature review there were very few cases of primary infection of a ventriculoperitoneal shunt with histoplasma capsulatum in an immunocompentent individual. We hope that this case report will help with consideration of this organism when presented with ventriculoperitoneal shunt infection in an immunocompetent patient.

Background NA

Design/Methods NA

Results NA

Conclusions NA

Authors/Disclosures
Sydney Moseley, MD (Sydney Moseley) PRESENTER	Dr. Moseley has nothing to disclose.
Alexandra Nee, MD	No disclosure on file
Kristina Maselli, MD (Montefiore Headache Center)	Dr. Maselli has nothing to disclose.
Robert Fekete, MD	Dr. Fekete has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine Biosciences, Inc.. Dr. Fekete has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acorda, Inc.. Dr. Fekete has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Fekete has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva Neuroscience, Inc.. Dr. Fekete has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acadia Pharmaceutical, Inc.. Dr. Fekete has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin, Inc.. Dr. Fekete has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Adamas Pharmaceutical, Inc.. Dr. Fekete has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurocrine Biosciences, Inc.. Dr. Fekete has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amneal Pharmaceuticals, Inc.. Dr. Fekete has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Acorda Therapeutics, Inc.. Dr. Fekete has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion, Inc.. Dr. Fekete has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink, Inc.. The institution of Dr. Fekete has received research support from Lundbeck. Dr. Fekete has received publishing royalties from a publication relating to health care. Dr. Fekete has a non-compensated relationship as a Neurological Working Group Member with Alliance for Patient Access that is relevant to �鶹��ýӳ�� interests or activities.

�鶹��ýӳ��

�鶹��ýӳ��